Issue link: http://osercommunicationsgroup.uberflip.com/i/709455
C h a i n D r u g s t o r e D a i l y M o n d a y, A u g u s t 8 , 2 0 1 6 8 4 $652 million. The transaction makes Mayne Pharma the second-largest provider of generic oral contraceptives in the United States. The 42-product portfolio included 37 commercialized and five pipeline products. "This acquisition transforms Mayne Pharma into a Top 25 player in the U.S. retail generic drug market – and the sec- ond-largest company providing generic oral contraceptives," said Scott Richards, Chief Executive Officer. "This well-bal- anced portfolio spans multiple dosage forms and complements our company's expertise in high-value and differentiated niche products. Even more importantly, this deal creates new opportunities for Mayne Pharma to build stronger and mutually beneficial relationships with our U.S. customers and suppliers." While the formulations of the acquired products remain the same, Mayne Pharma is committed to enhanc- ing the client experience, from ensuring the reliability of its supply to providing hands-on, attentive customer care. It understands what's important to pharma- Mayne P harma (C o nt'd. fro m p. 1 ) cists and the patients they serve: high- quality medicines, dependable supply and exceptional customer service. Mayne Pharma makes ordering easy – all you need are new NDC numbers, readily available online or from one of its team members. This acquisition comes as Mayne Pharma expands its physical presence in Greenville, North Carolina, constructing a 126,000-square-foot, large-scale, oral- dose facility to manufacture and package generic and branded drug products. The expansion will introduce commercial- scale manufacturing capability for modi- fied-release bead/pellet products and allow for the safe handling of multiple potent products at much greater capacity. With the expansion, Mayne Pharma becomes a global leader in advanced drug delivery, introducing to the United States highly specialized fluid-bed pro- cessing technologies that the company currently conducts in Australia. Look for Mayne Pharma team mem- bers; they would love to share NDC num- bers and more information about its generic portfolio acquisition. Visit Mayne Pharma at booth #1513. DS: Mondelēz International has invested in consumer snacking research to ensure we are focused on the big snacking growth moments. Snacking moments happen across the day, but people snack differently and have different drivers. We have gone beyond day parts and identified dis- tinct Snack Moments. A "Moment" is the intersection of a consumer, a need state and a consumption occasion. We grouped these occasions together based on common traits to create our focus Snack Moments: Highlight Wholesome, Help Meal Skippers, No Regret Treat, Delightful Variety, Premium Experience, Easier On-The- Go and Expand Entertaining. Understanding these Snack Moments, we continue to develop and refine our snack portfolio to ensure our snacks fulfill one or more of these needs sought throughout the day. CDD: How do your snacks help elevate a grocer's grab and go offerings? DS: Time compression has driven the need for portability and increased con- venience. With increasingly busy schedules, active lifestyles and demanding expectations, consumers are looking for ease on the go and function- al packaging to complement their snacking habits. Our Easier On-The-Go Snack Moment items deliver against the consumer need for away from home portable snacks. CDD: How do your snack foods fit into modern preferences for brighter, bolder flavors and cleaner ingredient lists? Snack Moments (C ont'd. from p. 1 ) DS: We have products that address the Delightful Variety and Highlight Wholesome Snack Moments. For Delightful Variety, strong flavor innova- tion has created new family favorites like Cinnamon Bun Flavored and Red Velvet Flavored OREO cookies. The OREO Wonder Vault continues to delight con- sumers with new and exciting flavors like our latest limited edition Choco Chip Flavored OREO cookies featuring a first- ever dual-flavored wafer, golden and chocolate, with chocolate chip flavored creme inside. For Highlight Wholesome, Original Triscuit is made with three sim- ple ingredients (wheat, oil and salt) and can be paired with a wide variety of fla- vorful toppings. We are inspiring new flavor varieties for everyday Triscuit, including our latest, Smoked Gouda, Mediterranean Olive and seasonal Limited Edition Sriracha! CDD: Many snack consumers are seek- ing low-guilt ways to indulge. How does your snack lineup address this need? DS: We know that many consumers are looking for light-textured sweet snacks that are delicious, but not too heavy. With that in mind we developed OREO Thins, a thin and crispy cookie that delivered on the OREO taste consumers love, but in a new, lighter-textured format. Originally launched in July 2015, OREO Thins now come in five varieties (Original, Golden, Mint, Lemon and Chocolate Creme) as well as a convenient on-the-go pack. Also, on August 1st, we introduced Chips Ahoy! Thins, thin, crispy cookies avail- able in two varieties (Chocolate Chip and Cinnamon Sugar). For more information, visit booth #2133 or call 973.503.2000. VK: Citron starts with great talent, and from the company's inception it has assembled a team of industry veterans and operational experts to execute on this strategy. The company distinguishes itself in the marketplace through its port- folio selection, partnering strategy and operational efficiency. In deploying its strategic vision, Citron focuses on bring- ing high-value, high barrier-to-entry products to the market, identifying and partnering with some of the best develop- ment and manufacturing companies in the world, and executing flawlessly to ensure an uninterrupted supply to the market. CDD: Where does Citron's current prod- uct emphasis fall? VK: Citron focuses on high-value, high barrier-to-entry products. We are not often chasing the latest products coming off patent, or the products with the high- est dollar value as measured by IMS. Citron is more interested in cultivating a unique portfolio in undersupplied mar- kets, where API is a constraint or where formulation expertise is a barrier to entry. Citron's product portfolio covers several therapeutic categories and dosage forms. CDD: Are you introducing any new products? If so, what distinguishes them from other products already on the mar- ket? VK: While we don't publicly comment on new products prior to launch, we can say that Citron maintains a full launch pipeline of products that will be intro- duced in the coming 12 months. We have launched an average of more than three products per quarter since early 2015, C itro n P harma (C o nt'd. fro m p. 1 ) and we are on track to maintain that pace in 2016 as well. CDD: How do Citron's services and products adapt to the ever-changing cus- tomer market to meet demands? VK: The value chain for generics includes the manufacturers, wholesalers and distributors, retail chains, pharma- cies and finally the consumer. Leveraging on the expertise that Citron has in every link of the value chain, Citron brings innovative solutions to the market in the forms of unique packaging, dosage strengths, speed to market, cus- tomer service and pharmacovigilance to serve all aspects of the market better. CDD: What are you doing today to ensure your company's long term suc- cess? What exciting developments are anticipated in Citron's future? VK: Citron continues to build on its existing portfolio at the same accelerated pace since its inception in 2013, and much of our near term portfolio will be introduced through our partnerships with world-class suppliers. However, the com- pany's future is being written today through the integration of key functional areas such as development, manufactur- ing and distribution. One of these prom- ising initiatives is already underway through an affiliated R&D company that currently has 30-plus projects under development for Citron. The company also recently broke ground on a manufac- turing and distribution center in the U.S. that will add a new level of capabilities that we can leverage for our customers. Visit Citron Pharma at booth #1101. For more information, go to www.citron pharma.com, call 855.55.CITRON or email contact@citronpharma.com. about the Prasco's approach to business? CA: We coined the phrase 'unlimit' in 2004. Although unlimit is a made-up word, the term makes a lot of sense to our customers and partners, because unlimit is not only a tag line but also a business philosophy. Prasco's corpo- rate approach is to remove barriers for partners and customers – to unlimit them. That is, we desire to introduce to customers and partners opportunities that they would not have otherwise had. CDD: Can you expound upon how the unlimit approach benefits customers? CA: Prasco's approach to business often results in products being available to cus- tomers in generic form for the first time. Since 2004, Prasco has launched 75 Authorized Generic (AG) products, and many times the only generic to the brand product is available exclusively from Prasco. Providing the first and sometimes only generic option to customers is certainly a pri- mary benefit of our unlimit philosophy. CDD: What benefit does your approach provide end-users of Prasco products? CA: End-users, or patients, certainly rec- ognize tangible benefits from Prasco Authorized Generics. First, Prasco AGs allow patients to obtain their prescription at a cost-savings as compared to the P rasco (C o nt'd. fro m p. 1 ) brand product. Second, because an Authorized Generic is identical to the brand product in every way, end-users have the same experience with an AG as they have with the brand. Prasco AGs have the same active and inactive ingre- dients as the brand product, but this is not the case with a typical generic product, which is only required to have the same active ingredients as the brand. We feel that offering end-users an experience with Prasco AGs that is identical to the experience they have had with the brand product can result in patients being more comfortable taking a Prasco AG as com- pared to a typical generic product. CDD: Authorized Generics have been Prasco's focus for many years. What's next for Prasco in this area? CA: We are a leader in Authorized Generics, and our mission is to extend that lead. Right now, only about half of the products on the market have an AG avail- able, so we still have work to do to increase that number. Prasco previously launched several AGs of older brand prod- ucts. We launched those products due to supply shortages in the marketplace. These supply shortages caused a significant neg- ative financial impact on the healthcare industry. This is yet another example of the need to expand the number of Authorized Generics in the marketplace. For more information, visit booth #617 or go to www.prasco.com.